间质性肺疾病相关咳嗽的治疗:CHEST指南与专家小组报告
该指南基于系统评价,纳入8项随机对照试验和2项病例系列(≥10例),评估间质性肺疾病(ILD)相关慢性咳嗽(≥8周)的治疗证据。指南建议对难治性咳嗽参照CHEST不明原因慢性咳嗽指南,考虑加巴喷丁等神经调节剂、言语病理学管理或阿片类药物;不推荐吸入糖皮质激素用于结节病相关咳嗽,不推荐环磷酰胺或霉酚酸酯仅用于治疗硬皮病相关ILD的咳嗽,沙利度胺推荐未通过专家投票。
要点
- ILD相关慢性咳嗽治疗证据有限,难治性咳嗽可参照CHEST不明原因慢性咳嗽指南。
- 可考虑加巴喷丁等神经调节剂、言语病理学管理或阿片类药物治疗难治性咳嗽。
- 不推荐吸入糖皮质激素治疗结节病相关咳嗽,不推荐环磷酰胺或霉酚酸酯仅用于硬皮病相关ILD咳嗽。
核心结论
- 支持ILD相关慢性咳嗽治疗措施的临床证据有限,指南基于最佳可用证据提出建议,未来仍需研究。
研究设计与样本
- 系统评价纳入8项随机对照试验和2项病例系列(≥10例患者),研究对象为年龄>18岁、慢性咳嗽≥8周的成人ILD患者。
- 研究质量评估显示所有8项随机对照试验均为高质量。
主要发现
- 纳入研究报告了特发性肺纤维化、结节病和硬皮病相关ILD患者接受多种干预的数据。
- 不推荐吸入糖皮质激素用于结节病相关咳嗽。
- 不推荐环磷酰胺和霉酚酸酯仅用于治疗硬皮病相关ILD的咳嗽。
- 沙利度胺治疗特发性肺纤维化相关咳嗽的推荐未通过专家小组投票。
关键数值与推荐
- 对于ILD难治性咳嗽,指南小组建议参照CHEST不明原因慢性咳嗽指南,考虑加巴喷丁等神经调节剂和言语病理学管理。
- 对替代治疗无效的咳嗽患者,建议使用阿片类药物。
临床怎么用
- 临床处理ILD相关慢性咳嗽时,应避免使用吸入糖皮质激素治疗结节病相关咳嗽。
- 不应仅用环磷酰胺或霉酚酸酯治疗硬皮病相关ILD的咳嗽。
- 对难治性咳嗽,可参照CHEST不明原因慢性咳嗽指南选择加巴喷丁、言语病理学管理或阿片类药物。
局限性
- 支持ILD相关慢性咳嗽管理的证据有限。
- 指南建议基于现有最佳证据,但未来研究明确需要。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chronic cough in interstitial lung disease (ILD) causes significant impairment in quality of life. Effective treatment approaches are needed for cough associated with ILD. METHODS: This systematic review asked: Is there evidence of clinically relevant treatment effects for therapies for cough in ILD? Studies of adults aged > 18 years with a chronic cough ≥ 8 weeks' duration were included and assessed for relevance and quality. Based on the systematic review, guideline suggestions were developed and voted on by using CHEST guideline methodology. RESULTS: Eight randomized controlled trials and two case series (≥ 10 patients) were included that reported data on patients with idiopathic pulmonary fibrosis, sarcoidosis, and scleroderma-related ILD who received a variety of interventions. Study quality was high in all eight randomized controlled trials. Inhaled corticosteroids were not supported for cough associated with sarcoidosis. Cyclophosphamide and mycophenolate were not supported for solely treating cough associated with scleroderma-associated ILD. A recommendation for thalidomide to treat cough associated with idiopathic pulmonary fibrosis did not pass the panel vote. In view of the paucity of antitussive treatment options for refractory cough in ILD, the guideline panel suggested that the CHEST unexplained chronic cough guideline be followed by considering options such as the neuromodulator gabapentin and speech pathology management. Opiates were also suggested for patients with cough refractory to alternative therapies. CONCLUSIONS: The evidence supporting the management of chronic cough in ILD is limited. This guideline presents suggestions for managing and treating cough on the best available evidence, but future research is clearly needed.
引用
- Birring SS, Kavanagh JE, Irwin RS, et al. Treatment of Interstitial Lung Disease Associated Cough: CHEST Guideline and Expert Panel Report. Chest. 2018. PMID: 30036496. doi:10.1016/j.chest.2018.06.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。